Bluejay Diagnostics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BJDX research report →
Price Chart
About the company
Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system.
- CEO
- Indranil Dey
- IPO
- 2021
- Employees
- 6
- HQ
- Acton, MA, US
Get TickerSpark's AI analysis on BJDX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.90M
- P/E
- -0.08
- Fwd P/E
- 0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.28
- EV/EBITDA
- 0.71
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -113.80%
- ROIC
- -104.23%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-6,952,972
- Net Income
- $-6,848,483+11.3%
- EPS
- $-61.00+96.7%
- OCF Growth
- +22.6%
- FCF Growth
- +23.4%
- 52W High
- $28.00
- 52W Low
- $1.62
- 50D MA
- $2.88
- 200D MA
- $6.61
- Beta
- 0.92
- RSI (14)
- 29
- Avg Volume
- 325.86K
No earnings-call transcripts are available for BJDX yet.
- Free Float
- 98.0%
- Shares Outstanding
- 1.12M
- Float Shares
- 1.09M
of shares held by institutions
8 13F filers
Buy/sell ratio 6.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Citadel Advisors LLC | 54.76K | ▲ 54.76K |
| Jane Street Group, LLC | 43.90K | ▲ 43.90K |
| Geode Capital Management, LLC | 39.60K | ▲ 39.60K |
| Susquehanna International Group, Llp | 27.68K | ▲ 27.68K |
| Stonex Group Inc. | 17.83K | ▲ 17.83K |
| Virtu Financial LLC | 12.03K | ▲ 12.03K |
| Vanguard Fiduciary Trust Co | 10.22K | 0 |
| Tower Research Capital LLC (Trc) | 2.93K | ▲ 1.03K |
| Ubs Group AG | 596 | ▲ 596 |
| L1 Global Manager Pty Ltd | 120 | 0 |
| Jpmorgan Chase & Co | 10 | ▲ 10 |
| Caitong International Asset Management Co., Ltd | 1 | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 17, 26 | ZEIDMAN FRED S | other | 100,000 |
| Aug 17, 26 | Wurth Douglas Clark | other | 100,000 |
| Aug 17, 26 | Dey Svetlana | other | 100,000 |
| Aug 17, 26 | Dey Indranil | other | 28,000 |
| Aug 17, 26 | CHASE DONALD R | other | 100,000 |
| Jul 21, 26 | BANK OF AMERICA CORP /DE/ | other | 0 |
| Jul 20, 26 | BANK OF AMERICA CORP /DE/ | other | 0 |
| Jul 9, 26 | HRT FINANCIAL LP | buy | 64,047 |
| Jul 10, 26 | HRT FINANCIAL LP | sell | 34,938 |
| Jul 9, 26 | HRT FINANCIAL LP | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BJDX coverage
Recent articles, reports, and earnings notes.
No research on BJDX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BJDX report →Bluejay Achieves Toray Contractual Manufacturing Milestone, Advancing Supply-Chain Resilience and Commercialization Readiness
accessnewswire.com · Oct 13
Bluejay Diagnostics Advances Rapid Biomarker Testing For Sepsis Patients
benzinga.com · Oct 6
Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock
accessnewswire.com · Oct 6
Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets
globenewswire.com · Sep 8
Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization
globenewswire.com · Aug 13
Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study
globenewswire.com · Jul 21
Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
globenewswire.com · Jun 5
What's Going On With Bluejay Diagnostics Shares On Wednesday?
benzinga.com · Jun 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.